SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions.
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer
